Current and Innovated Managements for Autoimmune Bullous Skin Disorders: An Overview
Autoimmune bullous skin disorders are a group of disorders characterized by the formation of numerous blisters and erosions on the skin and/or the mucosal membrane, arising from autoantibodies against the intercellular adhesion molecules and the structural proteins. They can be classified into intra...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical medicine 2022-06, Vol.11 (12), p.3528 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 12 |
| container_start_page | 3528 |
| container_title | Journal of clinical medicine |
| container_volume | 11 |
| creator | Chu, Kuan-Yu Yu, Hsin-Su Yu, Sebastian |
| description | Autoimmune bullous skin disorders are a group of disorders characterized by the formation of numerous blisters and erosions on the skin and/or the mucosal membrane, arising from autoantibodies against the intercellular adhesion molecules and the structural proteins. They can be classified into intraepithelial or subepithelial autoimmune bullous dermatoses based on the location of the targeted antigens. These dermatoses are extremely debilitating and fatal in certain cases, depending on the degree of cutaneous and mucosal involvement. Effective treatments should be implemented promptly. Glucocorticoids serve as the first-line approach due to their rapid onset of therapeutic effects and remission of the acute phase. Nonetheless, long-term applications may lead to major adverse effects that outweigh the benefits. Hence, other adjuvant therapies are mandatory to minimize the potential harm and ameliorate the quality of life. Herein, we summarize the current therapeutic strategies and introduce promising therapies for intractable autoimmune bullous diseases. |
| doi_str_mv | 10.3390/jcm11123528 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9224787</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2681042679</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-e2d901829645221c60c85c14231ec0f032f887e44fc849a5048658272f82a033</originalsourceid><addsrcrecordid>eNpdkc1LAzEQxYMoKtqTdwl4EaSaTLKbrAeh1q-C4sHeQ8xmdetuUpPdiv-9UatU55Ih78fjDQ-hPUqOGSvIycy0lFJgGcg1tA1EiCFhkq2v7FtoEOOMpJGSAxWbaItlgrOskNtoOu5DsK7D2pV44pxf6M6W-E47_WTbJERc-YBHfefrtu2dxed90_g-4oeX2uGLOvpQ2hBP8cjh-4UNi9q-7aKNSjfRDpbvDppeXU7HN8Pb--vJeHQ7NJwU3dBCWRAqoch5BkBNTozMDOXAqDWkIgwqKYXlvDKSFzojXOaZBJG-QRPGdtDZt-28f2xtaVLaoBs1D3Wrw7vyulZ_FVc_qye_UAUAF1Ikg8OlQfCvvY2dautobNNoZ9OJCnJJCYdcFAk9-IfOfB9cuk596oJT-Ep09E2Z4GMMtvoNQ4n67Eut9JXo_dX8v-xPO-wDe8iPOA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2679741203</pqid></control><display><type>article</type><title>Current and Innovated Managements for Autoimmune Bullous Skin Disorders: An Overview</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Chu, Kuan-Yu ; Yu, Hsin-Su ; Yu, Sebastian</creator><creatorcontrib>Chu, Kuan-Yu ; Yu, Hsin-Su ; Yu, Sebastian</creatorcontrib><description>Autoimmune bullous skin disorders are a group of disorders characterized by the formation of numerous blisters and erosions on the skin and/or the mucosal membrane, arising from autoantibodies against the intercellular adhesion molecules and the structural proteins. They can be classified into intraepithelial or subepithelial autoimmune bullous dermatoses based on the location of the targeted antigens. These dermatoses are extremely debilitating and fatal in certain cases, depending on the degree of cutaneous and mucosal involvement. Effective treatments should be implemented promptly. Glucocorticoids serve as the first-line approach due to their rapid onset of therapeutic effects and remission of the acute phase. Nonetheless, long-term applications may lead to major adverse effects that outweigh the benefits. Hence, other adjuvant therapies are mandatory to minimize the potential harm and ameliorate the quality of life. Herein, we summarize the current therapeutic strategies and introduce promising therapies for intractable autoimmune bullous diseases.</description><identifier>ISSN: 2077-0383</identifier><identifier>EISSN: 2077-0383</identifier><identifier>DOI: 10.3390/jcm11123528</identifier><identifier>PMID: 35743598</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Antigens ; Autoimmune diseases ; Clinical medicine ; Clinical trials ; Drug dosages ; Immunosuppressive agents ; Kinases ; Leukemia ; Lymphoma ; Monoclonal antibodies ; Patients ; Review ; Rheumatoid arthritis ; Skin diseases ; Tumor necrosis factor-TNF</subject><ispartof>Journal of clinical medicine, 2022-06, Vol.11 (12), p.3528</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c409t-e2d901829645221c60c85c14231ec0f032f887e44fc849a5048658272f82a033</citedby><cites>FETCH-LOGICAL-c409t-e2d901829645221c60c85c14231ec0f032f887e44fc849a5048658272f82a033</cites><orcidid>0000-0002-2955-458X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224787/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224787/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35743598$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chu, Kuan-Yu</creatorcontrib><creatorcontrib>Yu, Hsin-Su</creatorcontrib><creatorcontrib>Yu, Sebastian</creatorcontrib><title>Current and Innovated Managements for Autoimmune Bullous Skin Disorders: An Overview</title><title>Journal of clinical medicine</title><addtitle>J Clin Med</addtitle><description>Autoimmune bullous skin disorders are a group of disorders characterized by the formation of numerous blisters and erosions on the skin and/or the mucosal membrane, arising from autoantibodies against the intercellular adhesion molecules and the structural proteins. They can be classified into intraepithelial or subepithelial autoimmune bullous dermatoses based on the location of the targeted antigens. These dermatoses are extremely debilitating and fatal in certain cases, depending on the degree of cutaneous and mucosal involvement. Effective treatments should be implemented promptly. Glucocorticoids serve as the first-line approach due to their rapid onset of therapeutic effects and remission of the acute phase. Nonetheless, long-term applications may lead to major adverse effects that outweigh the benefits. Hence, other adjuvant therapies are mandatory to minimize the potential harm and ameliorate the quality of life. Herein, we summarize the current therapeutic strategies and introduce promising therapies for intractable autoimmune bullous diseases.</description><subject>Antigens</subject><subject>Autoimmune diseases</subject><subject>Clinical medicine</subject><subject>Clinical trials</subject><subject>Drug dosages</subject><subject>Immunosuppressive agents</subject><subject>Kinases</subject><subject>Leukemia</subject><subject>Lymphoma</subject><subject>Monoclonal antibodies</subject><subject>Patients</subject><subject>Review</subject><subject>Rheumatoid arthritis</subject><subject>Skin diseases</subject><subject>Tumor necrosis factor-TNF</subject><issn>2077-0383</issn><issn>2077-0383</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdkc1LAzEQxYMoKtqTdwl4EaSaTLKbrAeh1q-C4sHeQ8xmdetuUpPdiv-9UatU55Ih78fjDQ-hPUqOGSvIycy0lFJgGcg1tA1EiCFhkq2v7FtoEOOMpJGSAxWbaItlgrOskNtoOu5DsK7D2pV44pxf6M6W-E47_WTbJERc-YBHfefrtu2dxed90_g-4oeX2uGLOvpQ2hBP8cjh-4UNi9q-7aKNSjfRDpbvDppeXU7HN8Pb--vJeHQ7NJwU3dBCWRAqoch5BkBNTozMDOXAqDWkIgwqKYXlvDKSFzojXOaZBJG-QRPGdtDZt-28f2xtaVLaoBs1D3Wrw7vyulZ_FVc_qye_UAUAF1Ikg8OlQfCvvY2dautobNNoZ9OJCnJJCYdcFAk9-IfOfB9cuk596oJT-Ep09E2Z4GMMtvoNQ4n67Eut9JXo_dX8v-xPO-wDe8iPOA</recordid><startdate>20220619</startdate><enddate>20220619</enddate><creator>Chu, Kuan-Yu</creator><creator>Yu, Hsin-Su</creator><creator>Yu, Sebastian</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2955-458X</orcidid></search><sort><creationdate>20220619</creationdate><title>Current and Innovated Managements for Autoimmune Bullous Skin Disorders: An Overview</title><author>Chu, Kuan-Yu ; Yu, Hsin-Su ; Yu, Sebastian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-e2d901829645221c60c85c14231ec0f032f887e44fc849a5048658272f82a033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antigens</topic><topic>Autoimmune diseases</topic><topic>Clinical medicine</topic><topic>Clinical trials</topic><topic>Drug dosages</topic><topic>Immunosuppressive agents</topic><topic>Kinases</topic><topic>Leukemia</topic><topic>Lymphoma</topic><topic>Monoclonal antibodies</topic><topic>Patients</topic><topic>Review</topic><topic>Rheumatoid arthritis</topic><topic>Skin diseases</topic><topic>Tumor necrosis factor-TNF</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chu, Kuan-Yu</creatorcontrib><creatorcontrib>Yu, Hsin-Su</creatorcontrib><creatorcontrib>Yu, Sebastian</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chu, Kuan-Yu</au><au>Yu, Hsin-Su</au><au>Yu, Sebastian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Current and Innovated Managements for Autoimmune Bullous Skin Disorders: An Overview</atitle><jtitle>Journal of clinical medicine</jtitle><addtitle>J Clin Med</addtitle><date>2022-06-19</date><risdate>2022</risdate><volume>11</volume><issue>12</issue><spage>3528</spage><pages>3528-</pages><issn>2077-0383</issn><eissn>2077-0383</eissn><abstract>Autoimmune bullous skin disorders are a group of disorders characterized by the formation of numerous blisters and erosions on the skin and/or the mucosal membrane, arising from autoantibodies against the intercellular adhesion molecules and the structural proteins. They can be classified into intraepithelial or subepithelial autoimmune bullous dermatoses based on the location of the targeted antigens. These dermatoses are extremely debilitating and fatal in certain cases, depending on the degree of cutaneous and mucosal involvement. Effective treatments should be implemented promptly. Glucocorticoids serve as the first-line approach due to their rapid onset of therapeutic effects and remission of the acute phase. Nonetheless, long-term applications may lead to major adverse effects that outweigh the benefits. Hence, other adjuvant therapies are mandatory to minimize the potential harm and ameliorate the quality of life. Herein, we summarize the current therapeutic strategies and introduce promising therapies for intractable autoimmune bullous diseases.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>35743598</pmid><doi>10.3390/jcm11123528</doi><orcidid>https://orcid.org/0000-0002-2955-458X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2077-0383 |
| ispartof | Journal of clinical medicine, 2022-06, Vol.11 (12), p.3528 |
| issn | 2077-0383 2077-0383 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9224787 |
| source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Antigens Autoimmune diseases Clinical medicine Clinical trials Drug dosages Immunosuppressive agents Kinases Leukemia Lymphoma Monoclonal antibodies Patients Review Rheumatoid arthritis Skin diseases Tumor necrosis factor-TNF |
| title | Current and Innovated Managements for Autoimmune Bullous Skin Disorders: An Overview |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T18%3A38%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Current%20and%20Innovated%20Managements%20for%20Autoimmune%20Bullous%20Skin%20Disorders:%20An%20Overview&rft.jtitle=Journal%20of%20clinical%20medicine&rft.au=Chu,%20Kuan-Yu&rft.date=2022-06-19&rft.volume=11&rft.issue=12&rft.spage=3528&rft.pages=3528-&rft.issn=2077-0383&rft.eissn=2077-0383&rft_id=info:doi/10.3390/jcm11123528&rft_dat=%3Cproquest_pubme%3E2681042679%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2679741203&rft_id=info:pmid/35743598&rfr_iscdi=true |